Preclinical models have shown that receptor tyrosine kinase (RTK) inhibitors, particularly those targeting EGFR and FGFR, may suppress growth in YAP1-high SCLC cells [26,37,90]. Here, YAP1 is linked to small cell lung carcinoma.